Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
ARRY

Array BioPharma Inc

ARRY

16.36USD+0.55 (+3.48%)Delayed as of 11 Dec 2023, 11:04 am
Watchlist

Market Summary

USD16.36+0.55
Delayedas of 11 Dec 2023, 11:04 am
3.48%

ARRY Alerts

  • Big fall in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)

ARRY Stock Price

View Fullscreen

ARRY RSI Chart

ARRY Alerts

ARRY Valuation

Market Cap

2.4B

Price/Earnings (Trailing)

21.91

Price/Sales (Trailing)

1.46

EV/EBITDA

8.31

Price/Free Cashflow

10.85

ARRY Price/Sales (Trailing)

ARRY Profitability

Operating Margin

25.60%

EBT Margin

9.91%

Return on Equity

39.11%

Return on Assets

6.12%

Free Cashflow Yield

9.22%

ARRY Fundamentals

ARRY Revenue

Revenue (TTM)

1.6B

Revenue Y/Y

-31.96%

Revenue Q/Q

-30.98%

ARRY Earnings

Earnings (TTM)

108.9M

Earnings Y/Y

-42.88%

Earnings Q/Q

-64.18%

Price Action

52 Week Range

15.8626.64
(Low)(High)

Last 7 days

-2.8%

Last 30 days

5.3%

Last 90 days

-32.5%

Trailing 12 Months

-24.9%

How does ARRY drawdown profile look like?

ARRY Financial Health

Current Ratio

2.15

ARRY Investor Care

Shares Dilution (1Y)

0.48%

Diluted EPS (TTM)

0.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20231.7B1.8B1.6B0
2022905.7M1.1B1.5B1.6B
2021683.2M764.8M814.0M853.3M
2020811.5M975.1M916.8M872.7M
2019380.1M469.3M558.6M647.9M
2018000290.8M
Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for ARRY

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Oct 30, 2023
patel nipul m.
sold (taxes)
-19,908
18.00
-1,106
chief financial officer
Sep 01, 2023
hottinger tyson
sold
-187,825
25.0433
-7,500
chief legal officer
Aug 17, 2023
jokinen tracy c
acquired
-
-
7,051
-
Aug 14, 2023
patel nipul m.
sold
-1,262,190
23.12
-54,593
chief financial officer
Aug 11, 2023
hottinger tyson
sold
-198,220
23.32
-8,500
chief legal officer
Aug 03, 2023
collins terrance l
sold (taxes)
-27,943
18.83
-1,484
chief human resources officer
Jun 13, 2023
schmid gerrard
acquired
-
-
69.00
-
Jun 13, 2023
forth john bradford
acquired
-
-
69.00
-
Jun 13, 2023
alstead troy
acquired
-
-
69.00
-
Jun 13, 2023
almirante paulo
acquired
-
-
69.00
-

1–10 of 50

Which funds bought or sold ARRY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 06, 2023
CITIGROUP INC
reduced
-79.8
-1,930,640
477,506
 -%
Dec 06, 2023
Raleigh Capital Management Inc.
sold off
-100
-7,187
-
 -%
Dec 04, 2023
TUCKER ASSET MANAGEMENT LLC
sold off
-100
-61,992
-
 -%
Dec 01, 2023
B. Riley Wealth Advisors, Inc.
reduced
-60.95
-990,982
616,194
 0.02%
Nov 27, 2023
TRUST CO OF VERMONT
unchanged
-
-1,127
61,023
 -%
Nov 24, 2023
DEUTSCHE BANK AG\
reduced
-2.52
-1,620,130
36,118,700
 0.02%
Nov 22, 2023
Graham Capital Management, L.P.
sold off
-100
-858,280
-
 -%
Nov 22, 2023
KBC Group NV
unchanged
-
-
8,384,000
 0.04%
Nov 22, 2023
Polar Capital Holdings Plc
sold off
-100
-12,836,800
-
 -%
Nov 21, 2023
COMERICA BANK
new
-
2,278
2,278
 -%

1–10 of 33

Latest Funds Activity

Are funds buying ARRY calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ARRY
No. of Funds

Schedule 13G FIlings of Array BioPharma Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Nov 17, 2023
hill city capital, lp
5.14%
7,770,335
SC 13G
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.20%
13,841,925
SC 13G/A
Feb 08, 2023
invesco ltd.
3.5%
5,243,222
SC 13G/A
Jan 30, 2023
blackrock inc.
10.7%
16,134,994
SC 13G/A
Jan 17, 2023
norges bank
5.10%
7,679,550
SC 13G
Jan 17, 2023
norges bank
4.81%
7,233,072
SC 13G/A
Sep 01, 2022
blackstone holdings ii l.p.
4.2%
6,272,613
SC 13D/A
Jul 08, 2022
blackrock inc.
10.4%
15,607,696
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
0.8%
1,132,298
SC 13G/A

Recent SEC filings of Array BioPharma Inc

View All Filings
Date Filed Form Type Document
Nov 20, 2023
3
Insider Trading
Nov 17, 2023
SC 13G
Major Ownership Report
Nov 07, 2023
8-K
Current Report
Nov 07, 2023
10-Q
Quarterly Report
Nov 01, 2023
4
Insider Trading
Sep 05, 2023
4
Insider Trading

ARRY Fair Value

Loading...

Peers (Alternatives to Array BioPharma Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
FSLR
15.5B
3.2B
 5.48% -4.80%
32.77
4.91
 25.28% 400.24%
ENPH
14.1B
2.7B
 33.91% -67.81%
24.59
5.18
 34.37% 93.04%
MID-CAP
SEDG
4.5B
3.6B
 10.61% -75.15%
20.47
1.25
 28.13% 90.99%
RUN
2.8B
2.4B
 23.35% -55.61%
-2.36
1.19
 9.54% -1758.41%
ARRY
2.4B
1.6B
 5.33% -24.86%
21.91
1.46
 12.48% 991.33%
SHLS
2.3B
453.2M
 -8.97% -46.13%
16.4
4.98
 61.65% 712.35%
SMALL-CAP
SPWR
833.8M
1.9B
 17.53% -78.60%
13.18
0.44
 34.20% 140.78%
FTCI
93.7M
130.0M
 78.57% -70.36%
-1.57
0.72
 -34.52% 42.12%
BEEM
74.3M
69.3M
 -11.75% -74.51%
-3.95
1.07
 200.07% -35.41%
ASTI
48.7M
468.1K
 6.02% -99.86%
-2.84
103.96
 -62.86% 5.35%
SUNW
11.3M
154.9M
 -34.29% -89.25%
-0.18
0.07
 10.63% -80.26%

Array BioPharma Inc News

Latest updates
PR Newswire • 30 May 2023 • 07:00 am • 6 months ago
Oncothyreon and Array Announce Collaboration to Develop and ...
AlphaStreet • 26 Jul 2019 • 07:00 am • 4 years ago
Pfizer Inc. (PFE) Q2 2019 earnings preview
Investopedia • 18 Jun 2019 • 07:00 am • 4 years ago
Cancer Therapy Stocks Soar After Pfizer Deal
Business Wire • 17 Jun 2019 • 07:00 am • 4 years ago
Pfizer to Acquire Array BioPharma
Seeking Alpha • 22 May 2019 • 07:00 am • 4 years ago
High Short Interest, Strong Performance Stocks: May 2019
ETF Trends • 18 Apr 2019 • 07:00 am • 4 years ago
Traders Prepare For Earnings Season, Slow Growth Expectations
Seeking Alpha • 26 Mar 2019 • 07:00 am • 4 years ago
Biotech M&A Theme Builds Momentum
InvestorIdeas.com • 30 Aug 2018 • 06:22 pm • 5 years ago
Free biotech stocks directory, pharma stocks, telemedicine stocks ...
StreetInsider.com • 30 Aug 2018 • 07:00 am • 5 years ago
Form N-PX Managed Account Series For: Jun 30
PR Newswire • 27 Jun 2018 • 07:00 am • 5 years ago
Array BioPharma Announces FDA Approval of BRAFTOVI ...
Seeking Alpha • 09 May 2018 • 07:00 am • 5 years ago
Array BioPharma Inc. 2018 Q3 - Results - Earnings Call Slides ...
Nasdaq • 13 Feb 2018 • 08:00 am • 5 years ago
How to Uncover Institutional Buying
Markets Insider • 06 Feb 2018 • 08:00 am • 5 years ago
Encorafenib and Binimetinib Combination Treatment Demonstrates ...
PR Newswire • 19 Dec 2017 • 08:00 am • 5 years ago
Array BioPharma Announces Strategic Collaboration with Pfizer
PR Newswire • 16 Oct 2017 • 03:05 am • 6 years ago
Shalini Sharp Joins Array BioPharma Board of Directors

Financials for Array BioPharma Inc

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-31.0%350508377402515420301220189197248181139115438225198---
Cost Of Revenue-26.5%26335827632243538027421018317620214511393.00319164151---
Gross Profit-41.8%87.0015010181.0080.0040.0027.0010.006.0021.0046.0035.0027.0022.0011861.0047.00---
Operating Expenses-12.3%47.0054.0054.0064.0063.0053.0065.0030.0025.0021.0031.0038.0032.0021.0017.0020.0019.00---
  S&GA Expenses-7.0%37.0040.0038.0038.0039.0029.0045.0023.0018.0015.0025.0021.0012.0011.0012.0013.0010.00---
EBITDA Margin-1.5%0.16*0.17*0.12*0.08*0.05*-0.03*-0.03*0.00*0.03*0.05*0.04*0.14*0.18*0.20*0.22*0.17*0.18*---0.12*
Interest Expenses29.2%13.0010.0010.0010.009.008.007.007.0013.007.009.007.001.002.005.005.004.00---
Income Taxes-67.7%7.0022.0010.0014.0010.00-18.40-14.70-5.24-5.36-1.802.001.001.00-5.8323.009.006.00---
Earnings Before Taxes-65.1%30.0087.0036.009.0051.00-23.46-40.68-27.13-32.92-7.356.00-9.20-5.81-3.4496.0035.0024.00---
EBT Margin-2.1%0.10*0.10*0.04*0.00*-0.02*-0.11*-0.11*-0.07*-0.04*-0.01*-0.02*0.09*0.13*0.16*0.18*0.10*0.12*---0.28*
Net Income-64.2%23.0065.0026.00-5.2541.00-5.02-25.94-21.90-27.56-5.525.00-9.77-7.232.0074.0027.0018.00---
Net Income Margin-5.1%0.07*0.07*0.03*0.00*-0.01*-0.07*-0.09*-0.06*-0.05*-0.03*-0.02*0.07*0.10*0.12*0.14*0.06*0.09*---0.21*
Free Cashflow362.9%69.0015.0042.0094.00102-12.20-52.45-98.45-32.78-92.59-42.7210421.00-47.42-200397-4.10---3.45
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-4.0%1,7791,8531,7941,7061,7341,8191,7841,143770617586656552676800924820717613510
  Current Assets-5.0%863908867831871902816852485325288375265--620---174
    Cash Equivalents11.6%17415614813463.0051.0049.0036811618.0019.0010827.0038.001033613.00--41.00
  Inventory4.4%21620725523327033029920617313812511897.00--148---55.00
  Net PPE-3.8%30.0031.0026.0023.0020.0018.0017.0011.0010.0010.0010.0010.0010.00--11.00---11.00
  Goodwill-3.3%4274412.0041640141844270.0070.0070.0070.0070.0070.00--70.00---70.00
Liabilities-6.3%1,1621,2401,2751,2821,3351,4141,332975534689654737175323471618525432339245
  Current Liabilities-7.9%401435471465513513433245214168233289147--591---135
    LT Debt, Current3.5%39.0037.0034.0039.0048.0051.0048.004.004.004.004.004.00---56.00---20.00
    LT Debt, Non Current-6.2%659702706720725794778711299494392424-------59.00
Shareholder's Equity-3.1%278287207124111110170-69.201.00------305----
  Retained Earnings13.2%-153-176-241-267-262-302-297-271-250-222-216-221--------
  Additional Paid-In Capital-2.3%408418426383393402411203251150148140--------
Shares Outstanding-100.0%-151151-150150148-131127127-120120120120120--120
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations248.7%71,61820,54045,81697,470104,787-10,667-50,097-97,350-31,728-91,961-42,148104,29521,400-47,324-200,576397,593----
  Share Based Compensation-31.6%3,3844,9453,3663,3054,2052,9644,5082,0512,2391,5567,9111,5458536531,758799----
Cashflow From Investing60.5%-2,191-5,541-3,883-3,931-2,793-1,540-376,173-1,105-1,052-2,605-10,570-728-345-97.00-168-913----
Cashflow From Financing-190.2%-45,128-15,552-23,762-24,706-89,55121,961100,736349,734131,48993,115-36,590-22,270-31,895-17,416-57,692-38,271----

ARRY Income Statement

2023-09-30
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Revenue$ 350,438$ 515,024$ 1,234,936$ 1,235,475
Cost of revenue:    
Cost of product and service revenue259,419434,801892,6961,088,719
Amortization of developed technology3,6403,64010,91810,918
Total cost of revenue263,059438,441903,6141,099,637
Gross profit87,37976,583331,322135,838
Operating expenses:    
General and administrative37,43238,703115,825113,064
Change in fair value of contingent consideration190(572)2,232(5,981)
Depreciation and amortization9,55221,25829,36163,237
Total operating expenses47,17459,389147,418170,320
Income (loss) from operations40,20517,194183,904(34,482)
Other (expense) income:    
Other (expense), net(446)(1,092)(127)(2,295)
Interest income3,4257786,1242,371
Legal settlement042,750042,750
Foreign currency gain (loss)207(159)2731,968
Change in fair value of derivative assets1160(1,140)0
Interest expense(13,064)(8,831)(35,372)(23,812)
Total other (expense) income(9,762)33,446(30,242)20,982
Income (loss) before taxes30,44350,640153,662(13,500)
Income tax expense (benefit)7,2299,99639,508(23,183)
Net income23,21440,644114,1549,683
Preferred dividends and accretion13,09112,25738,35936,045
Net income (loss) to common shareholders, basic10,12328,38775,795(26,362)
Net income (loss) to common shareholders, diluted$ 10,123$ 28,387$ 75,795$ (26,362)
Income (loss) per common share    
Basic (in dollars per share)$ 0.07$ 0.19$ 0.50$ (0.18)
Diluted (in dollars per share)$ 0.07$ 0.19$ 0.50$ (0.18)
Weighted average number of common shares outstanding    
Basic (in shares)151,068150,322150,865149,604
Diluted (in shares)152,323151,382152,083149,604

ARRY Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 174,010$ 133,901
Accounts receivable, net of allowance of $1,418 and $1,888, respectively427,664421,183
Inventories216,018233,159
Income tax receivables3673,532
Prepaid expenses and other45,02939,434
Total current assets863,088831,209
Property, plant and equipment, net29,52123,174
Goodwill426,541416,184
Other intangible assets, net353,923386,364
Deferred income tax assets016,466
Derivative assets64,1300
Other assets41,55432,655
Total assets1,778,7571,706,052
Current liabilities:  
Accounts payable171,730170,430
Accrued expenses and other72,63854,895
Accrued warranty reserve2,5063,690
Income tax payable6,1436,881
Deferred revenue100,757178,922
Current portion of contingent consideration1,8141,200
Current portion of debt38,76738,691
Other current liabilities6,15510,553
Total current liabilities400,510465,262
Deferred income tax liabilities69,92872,606
Contingent consideration, net of current portion7,8057,387
Other long-term liabilities21,82014,808
Long-term warranty3,4211,786
Long-term debt, net of current portion658,879720,352
Total liabilities1,162,3631,282,201
Commitments and contingencies (Note 11)
Series A Redeemable Perpetual Preferred Stock of $0.001 par value - 500,000 authorized; 425,956 and 406,389 shares issued as of September 30, 2023 and December 31, 2022, respectively; liquidation preference of $493.1 million and $493.1 million at respective dates337,929299,570
Stockholders’ equity:  
Preferred stock of $0.001 par value - 4,500,000 shares authorized; none issued at respective dates00
Common stock of $0.001 par value - 1,000,000,000 shares authorized; 151,071,429 and 150,513,104 shares issued at respective dates151150
Additional paid-in capital407,916383,176
Accumulated deficit(153,316)(267,470)
Accumulated other comprehensive income23,7148,425
Total stockholders’ equity278,465124,281
Total liabilities, redeemable perpetual preferred stock and stockholders’ equity$ 1,778,757$ 1,706,052

About Array BioPharma Inc

ARRY
Array Technologies, Inc. manufactures and sells ground-mounting tracking systems used in solar energy projects in the United States, Spain, Brazil, Australia, and internationally. The company operates in two segments, Array Legacy Operations and STI Operations. Its products include DuraTrack HZ v3, a single axis tracker; Array STI H250 to deliver a lower levelized cost of energy with tracker system; Array OmniTrack; and SmarTrack, a software product that uses site-specific historical weather and energy production data in combination with machine learning algorithms to identify the optimal position for a solar array in real time to enhance its energy production. The company was founded in 1989 and is headquartered in Albuquerque, New Mexico.
 CEO
 WEBSITEarraytechinc.com
 EMPLOYEES1096

Array BioPharma Inc Frequently Asked Questions

What is the ticker symbol for Array BioPharma Inc? What does ARRY stand for in stocks?

ARRY is the stock ticker symbol of Array BioPharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Array BioPharma Inc (ARRY)?

As of Fri Dec 08 2023, market cap of Array BioPharma Inc is 2.39 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARRY stock?

You can check ARRY's fair value in chart. The fair value of Array BioPharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Array BioPharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARRY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Array BioPharma Inc a good stock to buy?

The fair value guage provides a quick view whether ARRY is over valued or under valued. Whether Array BioPharma Inc is cheap or expensive depends on the assumptions which impact Array BioPharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARRY.

What is Array BioPharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, ARRY's PE ratio (Price to Earnings) is 21.91 and Price to Sales (PS) ratio is 1.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARRY PE ratio will change depending on the future growth rate expectations of investors.